Who is sponsoring NCT06201000?

NCT06201000 is sponsored by October 6 University.

What drugs are being tested in NCT06201000?

Interventions in NCT06201000: SGLT2 inhibitors (Dapagliflozin and Empagliflozin).

What condition does NCT06201000 study?

NCT06201000 studies Genetic Polymorphisms, Heart Failure.

Is NCT06201000 still recruiting?

NCT06201000 is currently status unknown. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT06201000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Status unknown Last updated 7 February 2024

What this trial tests

trial testing SGLT2 inhibitors (Dapagliflozin and Empagliflozin) in Genetic Polymorphisms in 282 participants. Status unknown.

Timeline

27 December 2023

Primary endpoint
1 July 2024

1 September 2024

Quick facts

Lead sponsor	October 6 University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	282
Start date	27 December 2023
Primary completion	1 July 2024
Estimated completion	1 September 2024
Sites	1 location across United States

Drugs / interventions tested

SGLT2 inhibitors (Dapagliflozin and Empagliflozin) — full drug profile →

Conditions studied

Genetic Polymorphisms — all drugs for Genetic Polymorphisms →
Heart Failure — all drugs for Heart Failure →

Sponsor

October 6 University

Who can join

Adults 18 to 80, any sex, with Genetic Polymorphisms or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients. The SGLT2 gene, also known as SLC5A2 (solute carrier family 5 member 2), is located on chromosome 16 and is responsible for encoding SGLT2. Several SLC5A2 mutations alter SGLT2 expression, membrane location, or transporter function. Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Genetic polymorphisms in <i>SLC5A2</i> are associated with clinical outcomes and dapagliflozin response in heart failure patients.
Abou Warda AE, Flohr RM, Sarhan RM, Salem MN, et al · · 2025 · cited 3× · PMID 40356983 · DOI 10.3389/fphar.2025.1539870
Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis.
Xiao X, Huang G, Yu X, Tan Y. · · 2025 · cited 3× · PMID 39830783 · DOI 10.2147/dddt.s488226

Verify or expand the search:

Other recruiting trials for Genetic Polymorphisms

Currently open trials in the same condition.

NCT06978504 — Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome · NA · recruiting

Other October 6 University trials

Trials by the same sponsor.

NCT07235072 — Passive Fit and Time Efficiency in All On-X Implants Protocols Using Photogrammetry, Splinted Scan Bodies, and Conventio · NA · not yet recruiting
NCT07403851 — Effect of Scanning Technology on the Accuracy of Digitally Customized Intraradicular Attachments · NA · not yet recruiting
NCT07305792 — High Tone Power Therapy on Lumbosacral Radiculopathy Patients · NA · completed
NCT07132736 — Impact of Underwater Exercise Versus Regular Aerobic Exercise on Quality of Life and Power of Muscle · NA · recruiting
NCT07350655 — Efficacy of Virtual Reality-based Training in Patients With Chronic Non-specific Low Back Pain · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06201000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by October 6 University
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06201000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing